CA3134800A1 - Formulation de combinaison triple a faible dose - Google Patents

Formulation de combinaison triple a faible dose Download PDF

Info

Publication number
CA3134800A1
CA3134800A1 CA3134800A CA3134800A CA3134800A1 CA 3134800 A1 CA3134800 A1 CA 3134800A1 CA 3134800 A CA3134800 A CA 3134800A CA 3134800 A CA3134800 A CA 3134800A CA 3134800 A1 CA3134800 A1 CA 3134800A1
Authority
CA
Canada
Prior art keywords
dose
pharmaceutical composition
inhibitor
lowest
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3134800A
Other languages
English (en)
Inventor
Stephen Macmahon
Anthony Rodgers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
George Institute for Global Health
Original Assignee
George Institute for Global Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Institute for Global Health filed Critical George Institute for Global Health
Publication of CA3134800A1 publication Critical patent/CA3134800A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques qui sont utiles pour le traitement du diabète et d'affections, de maladies et de troubles associés. Les compositions comprennent a) un inhibiteur de dipeptidyle peptidase IV (DPPIV) tel que la sitagliptine, b) un inhibiteur de transport sodium-glucose de sous-type 2 (SGLT2) tel que la dapagliflozine ou l'empagliflozine, et c) un biguanide tel que la metformine. L'inhibiteur de DPPIV, l'inhibiteur de SGLT2 et le biguanide sont à une dose qui est environ égale à 20-75 % la dose thérapeutique pour le diabète la plus faible.
CA3134800A 2019-03-25 2020-03-25 Formulation de combinaison triple a faible dose Pending CA3134800A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/364,063 US11033544B2 (en) 2019-03-25 2019-03-25 Low-dose triple combination formulation
US16/364,063 2019-03-25
PCT/IB2020/000214 WO2020194052A1 (fr) 2019-03-25 2020-03-25 Formulation de combinaison triple à faible dose

Publications (1)

Publication Number Publication Date
CA3134800A1 true CA3134800A1 (fr) 2020-10-01

Family

ID=72606637

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3134800A Pending CA3134800A1 (fr) 2019-03-25 2020-03-25 Formulation de combinaison triple a faible dose

Country Status (11)

Country Link
US (5) US11033544B2 (fr)
EP (1) EP3946344A4 (fr)
JP (1) JP7586830B2 (fr)
KR (1) KR20220004027A (fr)
CN (2) CN119607213A (fr)
AU (2) AU2020247542A1 (fr)
BR (1) BR112021018994A2 (fr)
CA (1) CA3134800A1 (fr)
MX (2) MX2021011746A (fr)
TW (2) TW202545526A (fr)
WO (1) WO2020194052A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4368174A4 (fr) * 2021-07-08 2025-06-18 Hanmi Pharm. Co., Ltd. Comprimé oral complexe comprenant de la sitagliptine, de la dapagliflozine et de la metformine

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation
US20240374627A1 (en) * 2021-10-12 2024-11-14 Unison Pharmaceuticals Pvt. Ltd. A pharmaceutical composition comprising combination of sitagliptin and empagliflozin
TR2023001202A1 (tr) * 2023-02-02 2024-08-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇lm kapli empagliflozin ve metformin hi̇droklorür tabletleri̇
KR20260000968A (ko) * 2024-06-26 2026-01-05 주식회사 종근당 제2형 당뇨병 치료용 조성물, 조합물 및 병용 요법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
PL2395983T3 (pl) * 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
ES2900843T3 (es) * 2014-05-16 2022-03-18 Astrazeneca Ab Método para suprimir la secreción de glucagón de un inhibidor de sglt2
WO2016040462A2 (fr) * 2014-09-09 2016-03-17 ARKAY Therapeutics, LLC Formulations et méthodes de traitement du syndrome métabolique
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4368174A4 (fr) * 2021-07-08 2025-06-18 Hanmi Pharm. Co., Ltd. Comprimé oral complexe comprenant de la sitagliptine, de la dapagliflozine et de la metformine

Also Published As

Publication number Publication date
US20220226317A1 (en) 2022-07-21
KR20220004027A (ko) 2022-01-11
BR112021018994A2 (pt) 2022-02-08
CN119607213A (zh) 2025-03-14
TW202545526A (zh) 2025-12-01
CN113924096A (zh) 2022-01-11
AU2025226705A1 (en) 2025-09-25
MX2024013504A (es) 2024-12-06
US20220226315A1 (en) 2022-07-21
JP7586830B2 (ja) 2024-11-19
US20210260056A1 (en) 2021-08-26
JP2022529208A (ja) 2022-06-20
US11033544B2 (en) 2021-06-15
US20200306246A1 (en) 2020-10-01
EP3946344A4 (fr) 2022-12-28
TW202102209A (zh) 2021-01-16
EP3946344A1 (fr) 2022-02-09
WO2020194052A1 (fr) 2020-10-01
AU2020247542A1 (en) 2021-11-11
US20220226316A1 (en) 2022-07-21
MX2021011746A (es) 2021-10-22

Similar Documents

Publication Publication Date Title
US20220226315A1 (en) Synergistic combinations and methods of use
US20220184070A1 (en) Low-dose triple combination formulation
TWI472325B (zh) 包含經葡萄糖哌喃基取代之苯衍生物的醫藥組合物
CA2751834C (fr) Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp-iv et facultativement un autre agent antidiabetique et ses utilisations
EP2848254B1 (fr) Dérivé de pyrazole et son utilisation à des fins médicales
US20180311314A1 (en) Glucokinase Activator Compositions for the Treatment of Diabetes
KR102760956B1 (ko) 제미글립틴 및 다파글리플로진을 포함하는 경구용 복합제제, 및 이의 제조 방법
CN120713906A (zh) 用于治疗代谢失调的组合物和方法
HK40124034A (zh) 低剂量三联组合制剂
EP3954374A1 (fr) Combinaison pharmaceutique de pimozide et de méthotrexate et utilisation correspondante
HK40067275A (zh) 低剂量三联组合制剂
EP4008315A1 (fr) Processus pour des formulations de la dapagliflozine et du chlorhydrate de metformine
HK40067219A (zh) 低剂量三联组合制剂
CN119855596A (zh) 包含依那格列净代谢物的药物组合物及其用途
JPWO2002028398A1 (ja) 糖尿病治療用組成物
HK1134653A (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
HK1102424A1 (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240325

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250415

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250811

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250815

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250922

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250922

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250922

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250922

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260224